244 related articles for article (PubMed ID: 32580398)
21. Infiltration of CD3⁺ and CD68⁺ cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors.
Sjödahl G; Lövgren K; Lauss M; Chebil G; Patschan O; Gudjonsson S; Månsson W; Fernö M; Leandersson K; Lindgren D; Liedberg F; Höglund M
Urol Oncol; 2014 Aug; 32(6):791-7. PubMed ID: 24794251
[TBL] [Abstract][Full Text] [Related]
22. Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.
Rustamadji P; Wiyarta E; Pramono M; Maulanisa SC
Asian Pac J Cancer Prev; 2024 May; 25(5):1607-1613. PubMed ID: 38809632
[TBL] [Abstract][Full Text] [Related]
23. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer subtypes identified by the ER, PR and HER-2 status in Thai women.
Chuthapisith S; Permsapaya W; Warnnissorn M; Akewanlop C; Sirivatanauksorn V; Prasarttong Osoth P
Asian Pac J Cancer Prev; 2012; 13(2):459-62. PubMed ID: 22524806
[TBL] [Abstract][Full Text] [Related]
25. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
26. Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy.
Chen TH; Zhang YC; Tan YT; An X; Xue C; Deng YF; Yang W; Yuan X; Shi YX
Oncotarget; 2017 Jan; 8(3):5219-5232. PubMed ID: 28029650
[TBL] [Abstract][Full Text] [Related]
27. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
29. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
[TBL] [Abstract][Full Text] [Related]
30. High snail expression predicts a poor prognosis in breast invasive ductal carcinoma patients with HER2/EGFR-positive subtypes.
Chang HY; Tseng YK; Chen YC; Shu CW; Lin MI; Liou HH; Fu TY; Lin YC; Ger LP; Yeh MH; Liu PF
Surg Oncol; 2018 Jun; 27(2):314-320. PubMed ID: 29937187
[TBL] [Abstract][Full Text] [Related]
31. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer.
Takada K; Kashiwagi S; Goto W; Asano Y; Takahashi K; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
J Transl Med; 2018 Apr; 16(1):86. PubMed ID: 29615076
[TBL] [Abstract][Full Text] [Related]
32. Exploring the role CD163-labeled TAMs and FOXP3-labeled Tregs in different types of breast cancer: Reflections and putative benefits.
Shash LS; M Kamal KA; Abd Raboh NM
Indian J Pathol Microbiol; 2021; 64(1):28-37. PubMed ID: 33433406
[TBL] [Abstract][Full Text] [Related]
33. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
34. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients.
Medrek C; Pontén F; Jirström K; Leandersson K
BMC Cancer; 2012 Jul; 12():306. PubMed ID: 22824040
[TBL] [Abstract][Full Text] [Related]
35. The Role of CXCL13 and CXCL9 in Early Breast Cancer.
Razis E; Kalogeras KT; Kotsantis I; Koliou GA; Manousou K; Wirtz R; Veltrup E; Patsea H; Poulakaki N; Dionysopoulos D; Pervana S; Gogas H; Koutras A; Pentheroudakis G; Christodoulou C; Linardou H; Pavlakis K; Koletsa T; Pectasides D; Zagouri F; Fountzilas G
Clin Breast Cancer; 2020 Feb; 20(1):e36-e53. PubMed ID: 31699671
[TBL] [Abstract][Full Text] [Related]
36. Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer.
Raphael J; Gong IY; Nofech-Mozes S; Bartlett J; Nafisi H; Verma S
J Clin Pathol; 2016 Jun; 69(6):552-5. PubMed ID: 26951081
[No Abstract] [Full Text] [Related]
37. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
38. S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
Bergenfelz C; Gaber A; Allaoui R; Mehmeti M; Jirström K; Leanderson T; Leandersson K
Br J Cancer; 2015 Oct; 113(8):1234-43. PubMed ID: 26448179
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
40. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]